Skip to Content


In the US, Raltegravir (raltegravir systemic) is a member of the drug class integrase strand transfer inhibitor and is used to treat HIV Infection and Occupational Exposure.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antivirals for systemic use - Antiviral agent

Treatment of HIV infection

HIV integrase inhibitor

Chemical Names

N-[(4-Fluorophenyl)metyl]-5-hydroxy-1-metyl-2-[2-(5-metyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide (WHO)

4-Pyrimidinecarboxamide, N-((4-fluorophenyl)metyl)-1,6-dihydro-5-hydroxy-1-metyl-2-(1-metyl-1-(((5-metyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)etyl)-6-oxo-

5-Hydroxy-1-metyl-2-{1-metyl-1-[(5-metyl[1,3,4]oxadiazol-2-carbonyl)amino]etyl}-6-oxo-1,6-dihydropyrimidin-4-carbonsäure-4-fluorbenzylamid (IUPAC)


Foreign Names

  • Raltegravirum (Latin)
  • Raltegravir (German)
  • Raltégravir (French)
  • Raltegravir (Spanish)

Generic Names

Brand Names

  • Dutrebis [+ Lamivudine]
    Merck Sharp & Dohme, Lithuania; Merck Sharp & Dohme, Poland
  • Isentress
    Cibeles, Uruguay; Merck, Turkey; Merck Sharp & Dohme, Cyprus; Merck Sharp & Dohme, Greece; Merck Sharp & Dohme, Hong Kong; Merck Sharp & Dohme, Malaysia; Merck Sharp & Dohme, Netherlands; Merck Sharp & Dohme, Slovenia; Merck Sharp & Dohme, Taiwan; MSD, Costa Rica; MSD, Dominican Republic; MSD, Guatemala; MSD, Honduras; MSD, Nicaragua; MSD, Panama; MSD, Slovakia; MSD, El Salvador; MSD, Thailand; MSD, South Africa; MSD Italia, Italy; Merck Sharp & Dohme Pharma Singapore, Singapore
  • Dutrebis [+ Lamivudine]
    Merck Sharp & Dohme, United States
  • Isentress
    Merck Canada, Canada; Merck Sharp & Dohme, Australia; Merck Sharp & Dohme, Bosnia & Herzegowina; Merck Sharp & Dohme, Brazil; Merck Sharp & Dohme, Chile; Merck Sharp & Dohme, Estonia; Merck Sharp & Dohme, Spain; Merck Sharp & Dohme, United Kingdom; Merck Sharp & Dohme, Georgia; Merck Sharp & Dohme, Croatia (Hrvatska); Merck Sharp & Dohme, Iceland; Merck Sharp & Dohme, Lithuania; Merck Sharp & Dohme, Latvia; Merck Sharp & Dohme, New Zealand; Merck Sharp & Dohme, Poland; Merck Sharp & Dohme, Romania; Merck Sharp & Dohme, Serbia; Merck Sharp & Dohme, United States; MSD, Czech Republic; MSD, Denmark; MSD, Finland; MSD, France; MSD, Ireland; MSD, Japan; MSD, Norway; MSD, Peru; MSD, Sweden; MSD Argentina, Argentina; MSD Belgium, Belgium; MSD Merck Sharp & Dohme, Germany
  • Isentress (Merck Sharp & Dohme
    China MSD, China
  • Isentress 100mg
    MSD, Switzerland
  • Isentress 25mg
    MSD, Switzerland
  • Isentress 400mg
    Merck Sharp & Dohme, Austria; Merck Sharp & Dohme, Israel; MSD, Switzerland; MSD Belgium, Luxembourg; MSD Pharma, Hungary
  • Isentress 600mg
    Merck Sharp & Dohme, Austria; MSD Belgium, Luxembourg
  • Isentress HD
    Merck Canada, Canada; Merck Sharp & Dohme, Australia


BANBritish Approved Name
BANMBritish Approved Name (Modified)
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.